Shanti Amé

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Raphaël Itzykson, Sylvain Thépot, Bruno Quesnel et al. · Blood · 2010 · 386 citations · Full text

Medicine, Oncology, Pharmacology +10

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

Delphine Réa, Shanti Amé, Marc Berger et al. · Cancer · 2018 · 74 citations · Full text

Medicine, Hematology, Oncology +15

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

Jean‐Claude Chomel, Marie Laure Bonnet, Nathalie Sorel et al. · Oncotarget · 2016 · 63 citations · Full text

Medicine, Hematology, Pharmacology +16

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study

Franck E. Nicolini, Gabriel Étienne, Viviane Dubruille et al. · The Lancet Haematology · 2015 · 54 citations

Medicine, Hematology, Pharmacology +6

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

Maël Heiblig, Delphine Réa, Marie‐Lorraine Chrétien et al. · Experimental Hematology · 2018 · 44 citations

Medicine, Oncology, Pharmacology +16